Analyst Ratings for [TRVI] Trevi Therapeutics, Inc.

3/10/25	Reiterated	Buy	X
TRVI Trevi Therapeutics Needham
$8 $25
3/10/25	Upgrades	Outperform Strong Buy	X
TRVI Trevi Therapeutics Raymond James
$9 $29
12/12/24	Reiterated	Buy	X
TRVI Trevi Therapeutics H.C. Wainwright
$6 $7.50
9/9/24	Resumed	Outperform	X
TRVI Trevi Therapeutics Leerink Partners
$6 $7
8/30/24	Initiated	Buy	X
TRVI Trevi Therapeutics H.C. Wainwright
$6
8/30/24	Initiated	Outperform	X
TRVI Trevi Therapeutics Raymond James
$9
6/13/24	Initiated	Buy	X
TRVI Trevi Therapeutics Rodman & Renshaw
$7
4/12/23	Initiated	Buy	X
TRVI Trevi Therapeutics B. Riley Securities
$6
11/22/22	Initiated	Outperform	X
TRVI Trevi Therapeutics SVB Leerink
$6
6/3/19	Initiated	Outperform	X
TRVI Trevi Therapeutics BMO Capital Markets
$15
6/3/19	Initiated	Buy	X
TRVI Trevi Therapeutics Needham
$18
6/3/19	Initiated	Buy	X
TRVI Trevi Therapeutics Stifel
$20
6/3/19	Initiated	Outperform	X
TRVI Trevi Therapeutics SVB Leerink
$14

TRVI Trevi Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.